X

Trial Profile

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aclidinium bromide/formoterol (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms ASTUTE
Sponsors AstraZeneca

Most Recent Events

30 Jun 2017 Planned End Date changed from 24 Aug 2018 to 3 Dec 2018.
30 Jun 2017 Planned primary completion date changed from 24 Aug 2018 to 3 Dec 2018.
30 Jun 2017 Planned initiation date changed from 25 Aug 2017 to 4 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com